Our Approach

Ardelyx develops:

  • Innovative, minimally-systemic, small molecule and polymeric therapeutics that work exclusively in the GI tract to treat GI and cardio-renal diseases.
  • We have developed a proprietary drug discovery and design platform enabling us, in a rapid and cost-efficient manner, to discover and design novel drug candidates

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

Therapeutic Areas

We are developing our lead product candidate, tenapanor, for the treatment of irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia in end stage renal disease (ESRD) patients on dialysis. We are also developing RDX227675 , our lead product candidate from the RDX022 program, for the treatment of hyperkalemia, or high potassium, in chronic kidney disease (CKD) patients, with or without heart failure (HF). Ardelyx is also independently advancing several research programs focused in gastrointestinal (GI) and cardio-renal diseases.